Series evaluating imatinib in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms
| Reference . | n . | CHR (%) . | CMR (%) . | Follow-up in months, median (range) . | Resistance . | Deaths . |
|---|---|---|---|---|---|---|
| Baccarani et al Haematologica, 200730 | 27 | 100 | 100 | 25 (15-60) | — | — |
| Klion et al J Allergy Clin Immunol., 200931 | 17 | N/A | 88 | N/A | — | — |
| Helbig et al Hematol Oncol., 201033 | 16 | 100 | 100 | 36 (2-59) | — | — |
| Pardanani et al Leukemia, 201234 | 18 | 94 | 100 | 73 | 1 | 2 |
| Legrand et al Medicine, 201335 | 44 | 100 | 95 | 52 (1-100) | — | 1 |
| German Registry on Disorders of Eosinophils and Mast Cells (unpublished) | 64 | 100 | 90 | 77 (2-129) | 2 | 4 |
| Reference . | n . | CHR (%) . | CMR (%) . | Follow-up in months, median (range) . | Resistance . | Deaths . |
|---|---|---|---|---|---|---|
| Baccarani et al Haematologica, 200730 | 27 | 100 | 100 | 25 (15-60) | — | — |
| Klion et al J Allergy Clin Immunol., 200931 | 17 | N/A | 88 | N/A | — | — |
| Helbig et al Hematol Oncol., 201033 | 16 | 100 | 100 | 36 (2-59) | — | — |
| Pardanani et al Leukemia, 201234 | 18 | 94 | 100 | 73 | 1 | 2 |
| Legrand et al Medicine, 201335 | 44 | 100 | 95 | 52 (1-100) | — | 1 |
| German Registry on Disorders of Eosinophils and Mast Cells (unpublished) | 64 | 100 | 90 | 77 (2-129) | 2 | 4 |